Hemostemix (CVE:HEM) Trading 38.1% Higher – What’s Next?

Hemostemix Inc. (CVE:HEM – Get Free Report) was up 38.1% during mid-day trading on Thursday . The stock traded as high as C$0.15 and last traded at C$0.15. Approximately 605,625 shares were traded during trading, an increase of 51% from the average daily volume of 401,760 shares. The stock had previously closed at C$0.11.

Hemostemix Stock Performance

The stock has a market cap of C$20.91 million, a P/E ratio of -12.00 and a beta of 0.20. The stock’s fifty day moving average is C$0.09 and its 200 day moving average is C$0.07.

About Hemostemix

(Get Free Report)

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.

Further Reading

• Five stocks we like better than Hemostemix
• What Investors Need to Know to Beat the Market
• Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
• The How And Why of Investing in Oil Stocks
• Why Amazon’s Next Earnings Could Trigger a Stock Breakout
• Upcoming IPO Stock Lockup Period, Explained
• With This Kind of Data, The Fed Isn’t Cutting Rates This Year